Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO

Psychopharmacology

Volumn 233, Issue 19-20, 2016, Pages 3503-3512

  Girgis, Ragy R ^a   Slifstein, Mark ^a   D’Souza, Deepak ^b   Lee, Yih ^c,d   Periclou, Antonia ^c   Ghahramani, Parviz ^e   Laszlovszky, István ^f   Durgam, Suresh ^c   Adham, Nika ^c   Nabulsi, Nabeel ^b   Huang, Yiyun ^b   Carson, Richard E ^b   Kiss, Béla ^f   Kapás, Margit ^f   Abi Dargham, Anissa ^a   Rakhit, Ashok ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

^d Pharmaceutical Product Development   (United States)

^e Inncelerex   (United States)

^f GEDEON RICHTER LTD   (Hungary)

Author keywords

Antipsychotic; Cariprazine; Dopamine D2 receptor; Dopamine D3 receptor; Occupancy; Positron emission tomography; Schizophrenia; 11C (+) PHNO

Indexed keywords

CARIPRAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NAXAGOLIDE C 11; RADIOLIGAND; UNCLASSIFIED DRUG; CARBON; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DRD2 PROTEIN, HUMAN; DRD3 PROTEIN, HUMAN; NAXAGOLIDE; NEUROLEPTIC AGENT; OXAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; RADIOPHARMACEUTICAL AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EC50; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; OPEN STUDY; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; BRAIN; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PARTIAL AGONISM; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CARBON RADIOISOTOPES; DOPAMINE; DOPAMINE AGONISTS; DRUG PARTIAL AGONISM; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZINES; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84982131463     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4382-y     Document Type: Article

References (53)

1. APA (2000) Diagnostic and statistical manual of mental disorders, fourth edition, text revision. American Psychiatric Association, Washington DC
2. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676
3. Carson R, Barker W, Liow JS (2003) Design of a motion-compensation OSEM list-mode algorithm for resolution-recovery reconstruction for the HRRT. In: Metzier S (ed) 2003 I.E. nuclear science symposium (IEEE NUCLEAR SCIENCE SYMPOSIUM - CONFERENCE RECORD), Portland, OR, USA, pp 3281–3285
4. Debelle M, Faradzs-zade S, Szatmari B, Nagy K (2014) Cariprazine in negative symptoms of schizophrenia: post hoc analyses of a fixed-dose, placebo- and active-controlled trial. Eur Neuropsychopharmacol 24:S534
5. Debelle M, Németh G, Szalai E, Szatmári B, Harsányi J, Barabássy A, Laszlovszky I (2015) Cariprazine as monotherapy for the treatment of schizophrenia patients with predominant negative symptoms: a double-blind, active controlled trial. Eur Neuropsychopharamcol 25:S510
6. First MB, Williams JBW, Spitzer RL, Gibbon M (2007) Structured clinical interview for DSM-IV-TR Axis I disorders, clinical trials version (SCID-CT). Biometrics Research, New York State Psychiatric Institute, New York
7. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding YS, Huang Y, Laruelle M, Carson RE, Rabiner EA (2012) Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66:489–500
8. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S, Kapur S, Wilson AA (2007) Positron emission tomography quantification of [C-11]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27:857–871
9. Girgis R, Xu X, Miyake N, Easwaramoorthy B, Gunn R, Rabiner E, Abi-Dargham A, Slifstein M (2011) In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11]-(+)-PHNO. Neuropsychopharmacology:887–895
10. Girgis RR, Xu X, Gil RB, Hackett E, Ojeil N, Lieberman JA, Slifstein M, Abi-Dargham A (2015) Antipsychotic binding to the dopamine-3 receptor in humans: a PET study with [(11)C]-(+)-PHNO. Schizophr Res 168:373–376
11. Graff-Guerrero A, Mizrahi R, Agid O, Marcon H, Penny B, Rusjan P, Wilson AA, Zipursky RB, Kapur S (2009) The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34:1078–1086
12. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S (2010) Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273–287
13. Gross G, Drescher K (2012) The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol:167–210
14. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ (1997) Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. NeuroImage 6:279–2787
15. Gurevich EV, Joyce JN (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20:60–80
16. Guy W (1976) The abnormal movement scale. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, Rockville, MD, pp. 218–222 DHEW Publication No. 76-338
17. Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor E, Domány G, Tihanyi K, Szombathelyi Z (2011) Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 59:925–935
18. Gyertyán I, Sághy K (2004) Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav Pharmacol 15:253–262
19. Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Ágai Csongor E, Domány G, Kiss B, Szombathelyi Z (2008) Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. Behavioural characterisation of RG-15. Naunyn Schmiedeberg’s Arch Pharmacol 378:529–539
20. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533–1539
21. Kapás M, Mészáros G, Yu B, Shi J, Knoche B, Laszlovszky I, Bolton G (2008) Comparison of the pharmacokinetic behavior of RGH 188 in schizophrenic patients and healthy volunteers. Eur Neuropsychopharmacol 18:S433
22. Keator D, Mukherjee J, Preda A, Highum D, Gage A, Potkin S (2009) Dopamine D2 and D3 receptor occupancy of cariprazine in schizophrenic patients. Schizophr Bull 35:154
23. Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Ágai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328–340
24. Kiss B, Laszlovszky I, Horváth A, Némethy Z, Schmidt E, Bugovics G, Fazekas K, Gyertyán I, Ágai-Csongor E, Domány G, Szombathelyi Z (2008) Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. Neurochemical characterisation of RG-15. Naunyn Schmiedeberg’s Arch Pharmacol 378:515–528
25. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. NeuroImage 4:153–158
26. Laszlovszky I, Németh G, Mészáros GP, Kapás M, Brooks DJ, Pavese N, SZombathelyi Z (2007) Dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2, antagonist/partial agonist antipsychotic, in healthy volunteers. Eur Neuropsychopharmacol 17(Suppl 4):S455
27. Laszy J, Laszlovszky I, Gyertyán I (2005) Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179:567–575
28. McCormick PN, Kapur S, Graff-Guerrero A, Raymond R, Nobrega JN, Wilson AA (2010) The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology 35:1826–1835
29. Mészáros G, Kapás M, Borsos M, Laszlovszky I, Németh G, Tihanyi K, Szombathelyi Z (2007) Pharmacokinetics of RGH 188, a novel dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy male volunteers. Eur Neuropsychopharmacol 17:S451
30. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063–1073
31. Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R, Gobert A (2007) Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J Neurochem 100:1047–1061
32. Mizrahi R, Agid O, Borlido C, Suridjan I, Rusjan P, Houle S, Remington G, Wilson AA, Kapur S (2011) Effects of antipsychotics on D3 receptors: a clinical PET study in first episode antipsychotic naive patients with schizophrenia using [11C]-(+)-PHNO. Schizophr Res 131:63–68
33. Nakamura T, Kubota T, Iwakaji A, Imada M, Kapas M, Morio Y (2016) Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther 10:327–338
34. Nyberg S, Nakashima Y, Nordstrom AL, Halldin C, Farde L (1996) Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. Review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry Suppl 29:40–44
35. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266–1277
36. Potkin S, Keator D, Mukherjee J, Preda A, Highum D, Gage A, Xie J, Ghahramani P, Laszlovszky I (2009) Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol 19:S316
37. Rabiner E, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, Gunn RN, Laruelle M (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: studies in non-hman primates and transgenic mice. Synapse 63:782–793
38. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154–1165
39. Redden L, Rendenbach-Mueller B, Abi-Saab WM, Katz DA, Goenjian A, Robieson WZ, Wang Y, Goss SL, Greco N, Saltarelli MD (2011) A double-blind, randomized, placebo-controlled study of the dopamine D(3) receptor antagonist ABT-925 in patients with acute schizophrenia. J Clin Psychopharmacol 31:221–225
40. Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A, et al. (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther 275:1239–1246
41. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, Merlo-Pich E, Houle S, Gunn R, Rabiner EA, Laruelle M (2010) Imaging dopamine D-3 receptors in the human brain with positron emission tomography, [C-11]PHNO, and a selective D-3 receptor antagonist. Biol Psychiatry 68:392–399
42. Seeman P (2001) Antipsychotic drugs, dopamine receptors, and schizophrenia. Clin Neurosci Res 1:53–60
43. Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horvath A, Pasztor G, Kapas M, Gyertyan I, Farkas S, Innis RB, Halldin C, Gulyas B (2011) Occupancy of dopamine D(2) and D(3) and serotonin 5-HT(1)A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology 218:579–587
44. Sigala S, Missale C, Spano P (1997) Opposite effects of dopamine D2 and D3 receptors on learning and memory in the rat. Eur J Pharmacol 336:107–112
45. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19
46. Slifstein M, Rabiner EA, Gunn RN (2012) Imaging dopamine D3 receptors in vivo. In: Seeman P, Madras B, Johnson JE (eds) Imaging of the human brain in health and disease. Neuroscience-Net
47. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2011) In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol 668:355–365
48. Toth M, Varrone A, Steiger C, Laszlovszky I, Horvath A, Kiss B, Gyertyan I, Adham N, Halldin C, Gulyas B (2013) Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates. Synapse 67:258–264
49. Waters N, Lofberg L, Haadsma-Svensson S, Svensson K, Sonesson C, Carlsson A (1994) Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm Gen Sect 98:39–55
50. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94:11–19
51. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P, Wilson AA (2006) High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [C-11]-(+)-PHNO. Biol Psychiatry 59:389–394
52. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48:4153–4160
53. Zimnisky R, Chang G, Gyertyan I, Kiss B, Adham N, Schmauss C (2013) Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology 226:91–100